热门资讯> 正文
Kymera Therapeutics定价2.25亿美元股权发行
2024-08-20 14:50
- Clinical-stage biopharmaceutical company Kymera Therapeutics (NASDAQ:KYMR) priced an underwritten public offering of $225M shares and pre-funded warrants to purchase shares.
- Kymera (KYMR) announced the sale of ~2M shares and pre-funded warrants to purchase ~3.52M shares in the offering.
- The shares of common stock are being sold at a public offering price of $40.75 per share and the pre-funded warrants are being sold at a public offering price of $40.7499 per pre-funded warrant.
- Underwriters have a 30-day option to purchase up to an additional 828,220 shares.
- The offering is expected to close on August 21, 2024.
- Shares of Kymera (KYMR) dropped 5.5% during after-hours of trade on Monday.
More on Kymera Therapeutics
- Kymera Therapeutics, Inc. (KYMR) Q2 2024 Earnings Call Transcript
- Kymera Therapeutics: Solid Progress And No Change To My 'Buy' Rating
- Kymera Therapeutics announces proposed underwritten offering
- Kymera Therapeutics GAAP EPS of -$0.58 beats by $0.12, revenue of $25.7M beats by $13.15M
- Seeking Alpha’s Quant Rating on Kymera Therapeutics
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
